New hope for Alzheimer's? early trial tests DNL628
NCT ID NCT07328451
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 23 times
Summary
This early-stage study tests an experimental drug called DNL628 in people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body processes it. About 68 participants will receive either the drug or a placebo. This is a first step to see if DNL628 might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE, EARLY ONSET are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site(s)
RECRUITINGLondon, WC1N 3BG, United Kingdom
Conditions
Explore the condition pages connected to this study.